Non-alcoholic fatty liver disease (NAFLD) is associated with a thorough reprogramming of
hepatic metabolism. Epigenetic mechanisms, in particular those associated with …

Background & Aims microRNAs (miRNAs) are deregulated in non-alcoholic fatty liver
disease (NAFLD) and have been proposed as useful markers for the diagnosis and …

Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty
liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic …

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and
ranges from steatosis to steatohepatitis and to liver fibrosis. Lipotoxicity in hepatocytes …

Pyruvate kinase is a key regulator in glycolysis through the conversion of
phosphoenolpyruvate (PEP) into pyruvate. Pyruvate kinase exists in various isoforms that …

Background Obesity-associated chronic low-grade inflammation leads to dysregulation of
central lipid and glucose metabolism pathways leading to metabolic disorders. MicroRNAs …

Liver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease
(NAFLD) severity. However, this technique is invasive and occasionally associated with …

Non-alcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver
disease, worldwide. The molecular pathogenesis of NAFLD is complex, involving numerous …

Metabolic syndrome (MetS), which includes several clinical components such as abdominal
obesity, insulin resistance (IR), dyslipidemia, microalbuminuria, hypertension …

Vascular disease is the prime determinant to cardiovascular morbidities and mortalities,
which comprises the early vascular damage and subsequent cardiovascular events. Non …